secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001055726-25-000045
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Inovio shareholders elect eight directors, ratify auditor, approve executive compensation and equity plan
--------------------------------------------------------------------------------

- Eight directors elected: each received 7.3M-8.4M votes for, 0.6M-1.7M withheld, 11M broker non-votes.
- Ernst & Young ratified as auditor for FY2025: 19.3M for, 0.6M against, 0.2M abstain.
- Advisory say-on-pay passed: 7.9M for, 1.1M against, 0.2M abstain, 11M broker non-votes.
- Amendment and restatement of 2023 Omnibus Incentive Plan approved: 7.8M for, 1.2M against, 0.1M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000045/0001055726-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000045/ino-20250520.htm
  HTML page:      https://secwatch.observer/filing/0001055726-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer